Compass Therapeutics (NASDAQ:CMPX – Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share and revenue of ($0.60) million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 8:00 AM ET.
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, analysts expect Compass Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Compass Therapeutics Price Performance
Shares of CMPX stock opened at $1.86 on Monday. The business has a 50-day moving average of $2.12 and a 200 day moving average of $3.98. Compass Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.88. The stock has a market capitalization of $335.87 million, a PE ratio of -4.57 and a beta of 0.92.
Analyst Ratings Changes
Read Our Latest Report on CMPX
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CMPX. LPL Financial LLC boosted its holdings in shares of Compass Therapeutics by 4.7% in the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company’s stock worth $239,000 after purchasing an additional 2,000 shares during the period. Victory Capital Management Inc. increased its holdings in Compass Therapeutics by 20.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after purchasing an additional 2,164 shares during the period. Focus Partners Wealth lifted its stake in Compass Therapeutics by 16.2% in the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after acquiring an additional 2,206 shares during the period. Invesco Ltd. increased its holdings in Compass Therapeutics by 5.3% during the fourth quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after buying an additional 3,245 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Compass Therapeutics by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock valued at $619,000 after acquiring an additional 3,329 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.
Compass Therapeutics Company Profile
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.
Featured Stories
- Five stocks we like better than Compass Therapeutics
- 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
- Bearish Pressure Is Building Around These 3 Stocks
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
